Repeated amphetamine administration results in behavioral sensitization, an enduring behavioral transformation expressed after short and long periods of withdrawal. To investigate the participation of the opioid system in amphetamine-induced behavioral sensitization, we studied the effect of naloxone, an opioid receptor antagonist, on the expression of behavioral sensitization tested after short-(2 days) and long-term (14 days) withdrawal periods. In addition, using quantitative competitive RT-PCR, we examined the levels of m-opioid receptor (MOR) and d-opioid receptor (DOR) mRNA in the nucleus accumbens shell (NAcSh) and ventral tegmental area (VTA) of behaviorally sensitized rats, at these two withdrawal times. This study showed that whereas naloxone did not modify the expression of behavioral sensitization tested after 2 days of withdrawal, it completely blocked the expression when tested after 14 days of withdrawal. DOR and MOR mRNA levels were not modified in the NAcSh of rats expressing behavioral sensitization after 2 or 14 days of withdrawal. Conversely, DOR and MOR mRNA levels were elevated in the VTA of animals expressing behavioral sensitization after 2 days of withdrawal. However, whereas DOR mRNA returned to control levels, MOR mRNA levels remained elevated in animals expressing behavioral sensitization after 14 days of withdrawal. These results indicate a striking difference between the role played by opioid receptors in the expression of amphetamine-induced behavioral sensitization, when tested after short-or long-term withdrawal periods. In addition, our results support the notion that repeated amphetamine-induced changes in opioid receptor expression may contribute to the perpetuation of psychostimulant abuse and/or relapse.
INTRODUCTION
Drug addiction is a pathological behavior characterized by compulsive drug seeking and drug taking, despite severe adverse consequences. A key feature of addiction is the intensification of drug craving that occurs in human addicts with repeated drug exposure. This intensification is long lasting and can persist after years and even decades of abstinence, leading to a very high incidence of relapse. A prominent animal model for this persistent behavioral change is the long-lasting increase in locomotor response to drugs of abuse following repeated exposure. This increased response, termed behavioral sensitization, is thought to reflect plastic changes in neuronal circuits that determine the incentive value of external stimuli, rendering the circuits hypersensitive or sensitized Robinson and Berridge, 2000) .
Many of the changes that have been identified following repeated psychostimulant administration take place in the mesolimbic dopamine system, major components of which are the ventral tegmental area (VTA) and the nucleus accumbens (NAc). Rats repeatedly exposed to psychostimulants have consistently shown augmented dopaminergic transmission in the NAc, preferentially in the shell region (NAcSh) (Pierce and Kalivas, 1995) . Despite its evident importance, however, dopaminergic neurotransmission is only one component of the neural circuitry, termed the motive circuit, that mediates behavioral sensitization to psychostimulants (Pierce and Kalivas, 1997) .
Another neurotransmitter system known to be implicated in behavioral sensitization is the excitatory amino acid system (Wolf, 1998; Vanderschuren and Kalivas, 2000) . Glutamate receptor antagonists, as well as excitotoxic lesions of the prefrontal cortex (PFC), can block the development of behavioral sensitization to psychostimulants (Karler et al, 1989 (Karler et al, , 1994 Wolf and Khansa, 1991; Kalivas and Alesdatter, 1993; Schenk et al, 1993; Stewart and Druhan, 1993; Wolf and Jeziorski, 1993; Ohmori et al, 1994; Wolf et al, 1995; Cador et al, 1999) . Moreover, release of glutamate in the NAc and VTA is enhanced in amphetamine-sensitized rats (Xue et al, 1996; Wolf and Xue, 1998, 1999; Wolf et al, 2000) .
The opioid system, one of the neuronal systems that constitute the motive circuit, has been recognized for its involvement in locomotor as well as motivational and emotional behaviors (Di Chiara and North, 1992; Shippenberg and Elmer, 1998) . Anatomical and neurochemical evidence support the interaction between the opioidergic and dopaminergic systems within the motive circuit (Di Chiara and Imperato, 1988; Devine et al, 1993; Churchill and Kalivas, 1996; Feigenbaum and Howard, 1997; Svingos et al, 1996 Svingos et al, , 1998 Svingos et al, , 1999 Svingos et al, , 2001 Garzon and Pickel, 2001 ). In addition, in several different animal models of drug reinforcement, opioid receptor antagonists have been shown to attenuate the rewarding effects of psychostimulants (Menkens et al, 1992; Sala et al, 1995; Kuzmin et al, 1997) .
More recently, evidence supporting the interaction between the opioidergic and glutamatergic neuronal systems within the motive circuit has started to emerge. Electron microscopy studies in the VTA reveal the presence of m-opioid receptors (MOR) on axon terminals forming excitatory synapses ) and on inhibitory neurons projecting to the medial PFC (Svingos et al, 2001 ). In the NAc, NMDA receptors colocalize with MOR (Gracy et al, 1997) , and immunoreactive profiles for MOR and d-opioid receptors (DOR) are associated with excitatory synapses (Svingos et al, 1996 (Svingos et al, , 1998 . In addition, MOR activation in the NAc modulates NMDA-induced currents (Martin et al, 1997) and activation of DOR in the striatum modulates the increase in calcium-dependent, amphetamine-evoked, glutamate extracellular levels (Rawls and McGinty, 2000) .
Numerous reports support the evidence that psychostimulants affect the expression and function of opioid receptors within the nuclei of the motive circuit. Cocaine administered to various species, using many different treatment regimens, induced changes in the expression of opioid receptors and opioid-induced inhibition of adenylyl cyclase (Unterwald, 2001) . Based on this evidence, various investigators have studied the involvement of the endogenous opioid system in psychostimulant-induced behavioral sensitization. It is currently well established that the endogenous k-opioid system plays an important role in opposing behavioral alterations that occur as a consequence of repeated psychostimulant administration, including the initiation and long-term expression of behavioral sensitization (Shippenberg et al, 2001) . On the other hand, information regarding the role of MOR and DOR in behavioral sensitization is scarce. We and others have reported changes in the expression levels of MOR in the NAc and other nuclei of the motive circuit, after intermittent injections of amphetamine or cocaine that induce behavioral sensitization (Unterwald et al, 1992 (Unterwald et al, , 1994 Vecchiola et al, 1999) . Opioid-receptor-coupled adenylate cyclase activity was also found to be altered after repeated intermittent injections of cocaine (Sala et al, 1995; Unterwald et al, 1993; Unterwald and Cuntapay, 2000) . In addition, the opioid antagonist naltrexone blocks the induction of amphetamine and cocaine-induced behavioral sensitization (Balcells-Olivero and Vezina, 1997; Sala et al, 1995) , and Heidbreder et al (1996) reported the involvement of DOR in the induction but not the expression of cocaineinduced behavioral sensitization measured after a shortterm withdrawal period.
At present no studies have been done to show the participation of MOR and DOR after long-term withdrawal periods. The difference in withdrawal times is an important point to consider since sensitization occurs because of a time-dependent cascade of different cellular changes and, thus, the neuronal events accompanying locomotor sensitization differ between short-and long-term withdrawal periods (Pierce and Kalivas, 1997; White and Kalivas, 1998; Wolf, 1998; Vanderschuren and Kalivas, 2000) .
In the present study, we have investigated the involvement of opioid receptors in the expression of amphetamineinduced behavioral sensitization measured after short (2 days) and long (14 days) periods of withdrawal. In addition, we examined MOR and DOR mRNA levels in the NAcSh and VTA of rats expressing behavioral sensitization at these two stages of withdrawal.
METHODS

Drugs and Chemicals
d-Amphetamine was obtained from Laboratorios Chile (Santiago, Chile). Naloxone hydrochloride was from Research Biochemicals International (RBI; Natick, MA, USA). Chomczynski Reagent was from Winkler (Santiago, Chile). Random primers were obtained from Promega (Madison, WI, USA). Other reagents used for in vitro transcription, reverse transcription and PCR, as well as ethidium bromide and agarose, were from Gibco-BRL (Bethesda, MD, USA).
Animals
All procedures were in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats (Taconic, Germantown, NY, USA) were individually housed in the testing room maintained at constant temperature with a 12 h light/dark cycle. Food and water were available ad libitum except during locomotor testing. Rats (130-170 g) were allowed 1 week of habituation before any treatment began, at which time they had reached a weight of 190-230 g. All experiments were performed during the animals' light cycle.
Amphetamine Dosing Paradigm
The induction of behavioral sensitization consisted of four injections of amphetamine (1.5 mg/kg, i.p.) or saline (0.9% NaCl, 1 ml/kg, i.p.), administered once every other day. All injections were performed by the same experimenter, between 12:00 and 1:00 pm.
The expression of behavioral sensitization was tested on 2 days: the first (challenge 1), 2 days following the last induction injection, and the second (challenge 2), 14-15 days following the last induction injection. Table 1 shows the different experimental groups and the injections administered during the induction phase and the test for expression days.
Naloxone Treatment
Induction of sensitization was performed as described above. On the first test for expression of sensitization (2 days withdrawal), each group of animals was randomly divided in two: the saline-pretreated group received a saline injection preceded 10 min earlier by saline or naloxone (5 mg/kg, i.p.); the amphetamine-pretreated groups received an amphetamine challenge (1.5 mg/kg, i.p.) preceded 10 min earlier by saline or naloxone (5 mg/kg, i.p.). On the second test for expression of sensitization (14 days withdrawal) all groups of rats received a challenge injection of amphetamine (0.75 mg/kg, i.p.), administered 10 min after saline or naloxone (5 mg/kg, i.p.). Table 2 shows the different experimental groups and the injections administered during the induction phase and the test for expression days.
Locomotor Testing
Test sessions began with 1 h habituation to the locomotor testing cage, consisting of a 15 Â 47 Â 26 cm 3 cage equipped with two pairs of infrared lights located lengthwise, 5 cm above the floor, 25 cm apart. Test cages were identical to the home cages except that the floors were covered with stainlesssteel grids instead of wood shaving. Crossovers, which register upon breaking of consecutive photobeams, were used as a measure of horizontal locomotor activity. Stereotypy was not quantified because the primary behavior elicited by 1.5 mg/kg d-amphetamine injected i.p. was cage crossing, with some rearing performed at either end of the cage.
After the habituation period, rats were given an intraperitoneal injection of amphetamine or saline, and immediately returned to the test cages. Horizontal locomotor activity was monitored during the next 2 h. Following the testing period, animals were returned to their home cages.
Dissection of Brain Regions and Preparation of Total RNA
After the last locomotor testing session, rats were decapitated, brains rapidly removed and sectioned in coronal slices using an ice-cold rodent brain mold (ASI Instruments, Warren, MI). Coronal slices were frozen on microscope slides that were placed on top of a metal block in a dry ice/ethanol bath. Frozen coronal sections were stored at À801C until dissection. To minimize variability between time of drug treatment and animal sacrifice, rats from each experimental group (three groups, five rats per group) were sacrificed sequentially in a fixed interval of 8 min. Two separate experiments of 15 rats each were carried out for both the short and long withdrawal periods, in order to work with a maximum of 15 rats at a time.
Nucleus accumbens shell (NAcSh) and VTA were dissected by means of a micropuncher (1 mm diameter, kind gift of Dr Miklos Palkovits, NIMH, NIH, Bethesda, MD, USA), from 1-or 2-mm thick frozen coronal slices, respectively (approximate coordinates: bregma 0.7-1.7 for NAcSh and À4.8 to À6.8 for VTA). Total RNA was purified from dissected brain regions pooled from two to three brains, using Chomczynski Reagent and following the manufacturer's recommendations. Total RNA concentration was determined by spectrophotometer measurements at 260 nm.
Competitive Quantitative RT-PCR
Competitor RNA was obtained by in vitro transcription of plasmids containing deleted PCR fragments of MOR and DOR cDNA, kindly provided by Dr Beata Búzás (Uniformed Services University, Bethesda, MD, USA). Competitive quantitative RT-PCR was carried out by a modification of the method described by Búzás and Cox (1997) . Reverse transcription was performed on 35 ng of total RNA and varying amounts of competitor RNA (0.2 log difference between each tube; five tubes/sample). Reverse transcription reaction components and incubation conditions, and PCR reagents and primers, were as described (Búzás and Cox, 1997) . PCR was performed on an MJ Research thermocycler with the following conditions: after an initial 5 min incubation at 951C, amplification was carried out for 30 cycles at 95C1 for 30 s, 581C for 30 s, and 721C for 30 s. The last primer extension step was at 721C for 7 min.
Separation, Detection, and Quantification of PCR Products
A total of 10 ml of amplified products was separated on a 2% agarose gel, visualized by ethidium bromide staining under UV illumination and photographed using a Polaroid 57 type film. Photographs were scanned and the intensity of the bands was quantified using the UNSCAN-IT computer program.
For analyzing the results, the log of the ratio of pixels of target to competitor PCR bands was graphed as a function of the log of a known amount of competitor RNA added to the correspondent RT reaction. The GraphPad Prism 2.01 software was used for regression analysis and calculation of x-intercepts, which corresponds to the points at which the molar ratio of the target and competitor RNAs is equal.
Statistical Analysis
All statistical analysis was performed using Prism 2.01 GraphPad Software. Horizontal locomotor activity across test sessions was first analyzed by two-way ANOVA (treatment Â test day). Group differences on individual test days were assessed by one-way ANOVA followed by the Newman-Keuls Multiple Comparison Test (when three groups were analyzed) or by the Mann-Whitney U-test (when two groups were analyzed). Differences between groups on the same test day were assessed by one-way ANOVA followed by the Newman-Keuls Multiple Comparison Test. The number of copies of opioid receptor mRNA was analyzed by one-way ANOVA followed by the Newmann-Keuls Multiple Comparison Test. All data are reported as means+SEM.
RESULTS
Induction and Expression of Behavioral Sensitization
To induce behavioral sensitization, repeated amphetamine (1.5 mg/kg, i.p.) injections were paired with exposure of the animals to a distinct test environment. An acute injection of amphetamine administered on test session 1 produces an increase in the horizontal locomotor response (Figure 1 ; total crossovers during 120 min; test session 1: amph/amph, 25+5, n ¼ 5; sal/sal, 8+2, n ¼ 5; po0.05). The horizontal locomotor response to a fixed dose of amphetamine (1.5 mg/kg, i.p.) increased from test session 1 to test session 4 (Figure 1 ; test session 1: amph/amph, 25+5, n ¼ 5; test session 4: amph/amph, 62+7, n ¼ 5; po0.01). No significant difference in the horizontal locomotor response was observed across test sessions in the saline control animals (Figure 1 ; test session 1: sal/sal 8+2, n ¼ 5; test session 4: sal/ sal, 6+3, n ¼ 5).
Expression of behavioral sensitization was observed in response to an amphetamine challenge injection administered to amphetamine-pretreated animals after 2 days and 14 days of withdrawal (Figure 1 ; chall. 1: amph/amph, 66+6, n ¼ 4; sal/amph, 49+6, n ¼ 4, po0.05; chall. 2: amph/amph, 44+11, n ¼ 4; sal/amph, 8+1, n ¼ 4, po0.05). No significant increase in locomotor activity was observed in the saline control animals (Figure 1 ; chall. 1: sal/sal, 5+1, n ¼ 4; chall. 2: sal/sal, 5+1, n ¼ 4).
Effect of Naloxone on the Expression of AmphetamineInduced Behavioral Sensitization Measured 2 and 14 Days after Repeated Amphetamine Administration
To determine whether opioid receptors participate in the expression of amphetamine-induced behavioral sensitization, naloxone (5 mg/kg, i.p.), a selective, nonspecific opioid Figure 1 Induction and expression of behavioral sensitization produced by repeated amphetamine administration. Values are expressed as mean 7 SEM number of crossovers achieved during 120 min, in response to saline (sal) or amphetamine (amph) injections. Pretreatment consisted of four injections of sal (1 ml/kg) or amph (1.5 mg/ml/kg) administered once every other day. Amph challenge injections were administered after two (chall. 1; 1.5 mg/kg) and 14 (chall. 2; 0.75 mg/kg) days of withdrawal. The number of rats in the different groups are given in parentheses in the symbol legend. *po0.01, compared to test session 1; **po0.05, compared to sal/amph control group.
Neuropsychopharmacology
Amphetamine-induced behavioral sensitization K Magendzo and G Bustos receptor antagonist, was injected 10 min before a saline or amphetamine challenge injection administered to pretreated rats 2 or 14 days after withdrawal.
The expression of behavioral sensitization tested after 2 days of withdrawal was not significantly affected by naloxone (Figure 2a ; total crossovers during 120 min, amph/amph, 128+26, n ¼ 4; amph/amph+NLX, 109+36, n ¼ 4). In addition, no significant difference was observed between the locomotor activity induced by a saline challenge injection in the presence or absence of naloxone (Figure 2a ; sal/sal, 10+3, n ¼ 5; sal/sal+NLX, 8+5, n ¼ 5).
On the other hand, naloxone completely blocked the expression of behavioral sensitization when tested 2 weeks after withdrawal (Figure 2b ; amph/amph, 93+16, n ¼ 4; amph/amph+NLX, 29+12, n ¼ 4; po0.05), whereas the locomotor activity induced by an amphetamine challenge injection administered to saline-pretreated rats was not affected by naloxone (sal/amph, 27+11, n ¼ 4; sal/ amph+NLX, 25+5, n ¼ 4).
Quantification of MOR and DOR mRNA Levels Expressed in NAcSh and VTA of Rats Expressing Behavioral Sensitization after Short-and Long-Term Withdrawal Periods
The levels of DOR and MOR mRNA, expressed in the NAcSh and VTA, were quantified in order to investigate whether changes in opioid receptor mRNA levels could account for the difference in the role played by opioid receptors in the expression of behavioral sensitization when tested 2 or 14 days after withdrawal. Only animals that showed behavioral sensitization were considered for analysis.
DOR and MOR mRNA levels were quantified by competitive RT-PCR, as described under Methods. Figure  3 shows two representative photographs of gels loaded with the five RT-PCR reactions performed for each RNA sample (left panel), and their correspondent densitometric analysis curves (right panel).
No significant changes were observed in the levels of DOR or MOR mRNAs expressed in the NAcSh of behaviorally sensitized rats, tested 2 or 14 days after withdrawal (Figure 4a ; copies DOR mRNA (%)/ng total RNA; 2 days withdrawal: sal/ sal, 100+7.8, n ¼ 4; amph/amph, 106+3.8, n ¼ 5; 14 days withdrawal: sal/sal, 100+19.0, n ¼ 3; sal/amph, 99.5+3.4, n ¼ 4; amph/amph, 82.7+9.2, n ¼ 4; Figure 4b ; copies MOR mRNA (%)/ng total RNA; 2 days withdrawal: sal/sal, 100+11.2, n ¼ 4; amph/amph, 116+9.6, n ¼ 5; 14 days withdrawal: sal/sal, 100+14.4, n ¼ 3; amph/amph, 91.5+14.0, n ¼ 4).
On the other hand, a significant increase in both DOR and MOR mRNA levels was observed in the VTA of rats expressing behaviorally sensitization when tested after 2 days of withdrawal (Figure 5a ; copies DOR mRNA (%)/ng total RNA, sal/sal, 100+22.7, n ¼ 3; amph/amph, 192.7+36.1, Figure 2 Effect of naloxone on the expression of behavioral sensitization tested 2 and 14 days after withdrawal. Values are expressed as mean 7 SEM number of crossovers achieved during 120 min, in response to challenge injections. Pretreatment consisted of four injections of saline (sal; 1 ml/kg) or amphetamine (amph; 1.5 mg/kg), administered once every other day. (a) After 2 days of withdrawal, challenge injections of amph (1.5 mg/kg) or sal were administered in the presence or absence of naloxone (NLX; 5 mg/kg). (b) After 14 days of withdrawal, all rats received an amphetamine challenge injection (0.75 mg/kg), administered in the presence or absence of naloxone. The number of rats in the different groups are given in parentheses in the symbol legend. *po0.05.
Amphetamine-induced behavioral sensitization K Magendzo and G Bustos n ¼ 4, po0.05; Figure 5b ; copies MOR mRNA (%)/ng total RNA, sal/sal, 100+66.1, n ¼ 3; amph/amph, 382.4+54.8, n ¼ 4; po 0.05). The increase in amphetamine-induced DOR mRNA was transient, returning to control levels when sensitization was tested 14 days after withdrawal (Figure 5a ; copies DOR mRNA (%)/ng total RNA, sal/sal, 100+21.5, n ¼ 5; sal/amph, 59.57+36.0, n ¼ 3; amph/amph, 107.5+11.8, n ¼ 4). On the other hand, the levels of MOR mRNA remained elevated when sensitization was tested 14 days after withdrawal (Figure 5b ; copies MOR mRNA (%)/ng total RNA, sal/sal, 100+14.0, n ¼ 4; sal/amph, 101.2+17.8, n ¼ 4; amph/amph, 192.6+4.7, n ¼ 4; po0.05).
DISCUSSION
This study shows that an initial four every-other-day exposure to amphetamine induced behavioral sensitization, which was expressed following a challenge amphetamine injection administered 2 or 14 days after withdrawal. Naloxone did not modify the expression of behavioral sensitization when tested 2 days after withdrawal. In contrast, the expression of behavioral sensitization tested after 14 days of withdrawal was completely blocked by the opioid antagonist.
The analysis of MOR and DOR mRNA expression showed that DOR and MOR mRNA levels in the NAcSh were not modified in response to a challenge amphetamine injection administered after 2 or 14 days of drug discontinuation. On the other hand, DOR and MOR mRNA levels were elevated in the VTA of animals expressing behavioral sensitization after 2 days of withdrawal. However, whereas DOR mRNA returned to control levels, MOR mRNA levels remained elevated in the VTA of animals expressing behavioral sensitization after 14 days of withdrawal.
Behavioral Studies
Our results indicate a striking difference between the role played by opioid receptors in the expression of amphetamine-induced behavioral sensitization, when tested 2 or 14 days after drug withdrawal. While locomotor sensitization to amphetamine is expressed at each of these test times, numerous lines of evidence show that the accompanying neuronal events are different (Pierce and Kalivas, 1997) . For example, the manifestation of augmented dopamine transmission depends on the time after discontinuing the sensitization drug treatment regimen. During the first week of withdrawal, no change, decreases and increases in the ability of stimulants to elevate extracellular dopamine levels have been observed in the NAc and striatum of the Amphetamine-induced behavioral sensitization K Magendzo and G Bustos rat (Pierce and Kalivas, 1997) . After more lengthy withdrawal periods (two or more weeks), increased dopamine transmission is consistently associated with the expression of behavioral sensitization (Pierce and Kalivas, 1997) . Our observation that the expression of behavioral sensitization is not blocked at short-term withdrawal periods is consistent with that of Heidbreder et al (1996) , which shows that the administration of naltrindole, a DOR antagonist, does not block the expression of behavioral sensitization when given 2 days after cocaine pretreatment.
In this study we show that naloxone does not alter locomotor activity in response to an amphetamine challenge injection administered to saline-pretreated animals. This observation argues against the possibility that naloxoneinduced blockade of the expression of behavioral sensitization tested after 14 days of withdrawal results from a generalized disruption of behavior.
Expression Studies
In order to investigate whether changes in opioid receptor mRNA levels could account for the difference in the role played by opioid receptors in the expression of behavioral sensitization tested after short-or long-term withdrawal periods, the levels of MOR and DOR mRNA were quantified in the NAcSh and VTA. In the present study we report no changes in MOR mRNA levels in the NAcSh of rats expressing behavioral sensitization tested after 2 days of abstinence. These results are consistent with those of Unterwald et al (2001) which, using RNase-protection assay (RPA), reported that intermittent cocaine administration produces a transient increase in MOR mRNA levels in the NAc of rats after the first injection day, returning to basal levels after 7 or 14 days of binge-pattern cocaine administration. However, we have previously reported, using quantitative in situ hybridization (ISH), a significant decrease in MOR mRNA in the NAcSh of rats expressing behavioral sensitization following repeated intermittent administration (Vecchiola et al, 1999) .
This discrepancy may be explained by the existence of neuronal heterogeneity within the NAcSh. When using RT-PCR and RPA methodologies, the quantification corresponds to the levels of mRNA expressed in the entire NAcSh, which must be dissected out for RNA extraction and analysis. On the other hand, when using the method of ISH, the quantification corresponds to mRNA levels expressed on discrete regions of the NAcSh. Thus, if the NAcSh is a neuroanatomically heterogeneous brain nucleus, the levels of DOR or MOR mRNA expressed by a discrete set of neurons may differ from the net DOR or MOR mRNA levels expressed in the whole nucleus.
In this report we show that both DOR and MOR mRNA levels were elevated in the VTA of rats expressing behavioral sensitization when tested after short-term drug withdrawal. However, whereas DOR mRNA returned to control levels, MOR mRNA levels remained elevated in the VTA of animals expressing behavioral sensitization after 14 days of withdrawal. This is the first study, to our knowledge, that shows long-lasting effects of amphetamine-induced MOR expression.
It is generally accepted that the processes of initiation and expression of behavioral sensitization are not only temporally but also anatomically distinct. Initiation of behavioral sensitization to psychostimulants occurs in the VTA, whereas the neuronal events associated with expression are distributed among the interconnected nuclei of the motive circuit (Pierce and Kalivas, 1997) . However, various studies have identified changes in the VTA that may contribute to the expression of behavioral sensitization. Thus, repeated cocaine injections result in long-term changes in the presynaptic regulation of GABA transmission by D1 receptors in the VTA (Bonci and Williams, 1996) . Repeated cocaine injections also influence the release of glutamate in the VTA. Thus, cocaine administration enhances extracellular glutamate levels in the VTA of rats pretreated 21 days earlier with daily cocaine (Kalivas and Duffy, 1998) . The enhanced releasability of glutamate in the VTA of sensitized rats is consistent with electrophysiological observations that at 10, but not 2 days after discontinuing repeated amphetamine the excitatory response elicited in dopamine cells by stimulating excitatory amino acid afferents from the PFC is increased (Tong et al, 1995) .
The functional significance of the differential amphetamine-induced regulation of MOR and DOR mRNA levels in the VTA of rats expressing behavioral sensitization after short and long periods of withdrawal is not understood. However, the behavioral data using the opioid receptor antagonist naloxone suggest a relation between the amphetamine-induced increase in MOR but not DOR mRNA levels, after 14 days of withdrawal, and the expression of behavioral sensitization at this stage. Further experiments will be necessary to resolve this issue. Nevertheless, our results support the notion that amphetamine-induced changes in opioid receptor expression may contribute to the perpetuation of psychostimulant abuse and/or relapse.
